Skip to content
10-K

Annual Report

Verrica Pharmaceuticals Inc. VRCA

0001660334-26-000008

← back to feed
Filed
Mar 11, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 2, 2026 17.18M sh
Shares Diluted FY 2025 · Dec 31, 2025 10.65M sh
Shares Diluted restated FY 2025 · Dec 31, 2024 5.18M sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $27K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$17.63M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$60.93M
Long Term Debt FY 2025 · Dec 31, 2025 $0
Long Term Debt FY 2025 · Dec 31, 2024 $30.98M
Cash And Equivalents FY 2025 · Dec 31, 2025 $30.15M
Cash And Equivalents FY 2025 · Dec 31, 2024 $46.33M
Stockholders Equity FY 2025 · Dec 31, 2025 $24.74M
Stockholders Equity FY 2025 · Dec 31, 2024 −$9.86M
Stockholders Equity FY 2025 · Dec 31, 2023 $19.76M
Current Liabilities FY 2025 · Dec 31, 2025 $16.44M
Current Liabilities FY 2025 · Dec 31, 2024 $29.01M
Total Liabilities FY 2025 · Dec 31, 2025 $22.39M
Total Liabilities FY 2025 · Dec 31, 2024 $63.99M
Current Assets FY 2025 · Dec 31, 2025 $42.54M
Current Assets FY 2025 · Dec 31, 2024 $51.18M
Total Assets FY 2025 · Dec 31, 2025 $47.13M
Total Assets FY 2025 · Dec 31, 2024 $54.13M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.68
Eps Diluted restated FY 2025 · Dec 31, 2024 −$14.78
Eps Basic FY 2025 · Dec 31, 2025 −$1.68
Eps Basic restated FY 2025 · Dec 31, 2024 −$14.78
Sga Expense FY 2025 · Dec 31, 2025 $35.22M
Sga Expense FY 2025 · Dec 31, 2024 $58.82M
Rd Expense FY 2025 · Dec 31, 2025 $8.86M
Rd Expense FY 2025 · Dec 31, 2024 $11.84M
Rd Expense FY 2025 · Jul 21, 2023 $4.5M
Net Income FY 2025 · Dec 31, 2025 −$17.89M
Net Income FY 2025 · Dec 31, 2024 −$76.58M
Operating Income FY 2025 · Dec 31, 2025 −$12.19M
Operating Income FY 2025 · Dec 31, 2024 −$65.92M
Stock Issued FY 2025 · Nov 23, 2025 6.5M sh
Stock Issued FY 2025 · Nov 30, 2024 4.55M sh